Gan & Lee Pharmaceuticals Co Ltd (SHG:603087) — Market Cap & Net Worth
Market Cap & Net Worth: Gan & Lee Pharmaceuticals Co Ltd (603087)
Gan & Lee Pharmaceuticals Co Ltd (SHG:603087) has a market capitalization of $6.42 Billion (CN¥43.88 Billion) as of September 27, 2026. Listed on the SHG stock exchange, this China-based company holds position #3039 globally and #380 in its home market, demonstrating a 6.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gan & Lee Pharmaceuticals Co Ltd's stock price CN¥73.44 by its total outstanding shares 597432169 (597.43 Million). Also see Gan & Lee Pharmaceuticals Co Ltd (603087) total assets for a full breakdown of the balance sheet.
Gan & Lee Pharmaceuticals Co Ltd Market Cap History: 2020 to 2026
Gan & Lee Pharmaceuticals Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $11.45 Billion to $6.42 Billion (2.16% CAGR). Also see cash efficiency ratio of Gan & Lee Pharmaceuticals Co Ltd for how efficiently the company converts equity into cash flow.
Gan & Lee Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Gan & Lee Pharmaceuticals Co Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.47x
Gan & Lee Pharmaceuticals Co Ltd's market cap is 1.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.20x
Gan & Lee Pharmaceuticals Co Ltd's market cap is 5.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $11.45 Billion | $3.36 Billion | $1.23 Billion | 3.41x | 9.30x |
| 2021 | $6.11 Billion | $3.61 Billion | $1.45 Billion | 1.69x | 4.21x |
| 2022 | $2.85 Billion | $1.71 Billion | -$439.52 Million | 1.66x | N/A |
| 2023 | $4.60 Billion | $2.61 Billion | $340.07 Million | 1.76x | 13.53x |
| 2024 | $3.86 Billion | $3.05 Billion | $614.66 Million | 1.27x | 6.27x |
| 2025 | $5.95 Billion | $4.05 Billion | $1.14 Billion | 1.47x | 5.20x |
Competitor Companies of 603087 by Market Capitalization
Companies near Gan & Lee Pharmaceuticals Co Ltd in the global market cap rankings as of September 27, 2026. Review Gan & Lee Pharmaceuticals Co Ltd (603087) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Gan & Lee Pharmaceuticals Co Ltd by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #180 globally with a market cap of $132.26 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #357 globally with a market cap of $77.90 Billion USD ( €66.63 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #418 globally with a market cap of $67.43 Billion USD ( €57.68 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #545 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Intuitive Surgical Inc | NASDAQ:ISRG | $132.26 Billion | $405.18 |
| #357 | EssilorLuxottica S. A. | PA:EL | $77.90 Billion | €143.90 |
| #418 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $67.43 Billion | €71.50 |
| #545 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Gan & Lee Pharmaceuticals Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Gan & Lee Pharmaceuticals Co Ltd's market cap moved from $11.45 Billion to $ 6.42 Billion, with a yearly change of 2.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥6.42 Billion | +7.89% |
| 2025 | CN¥5.95 Billion | +54.35% |
| 2024 | CN¥3.86 Billion | -16.24% |
| 2023 | CN¥4.60 Billion | +61.60% |
| 2022 | CN¥2.85 Billion | -53.38% |
| 2021 | CN¥6.11 Billion | -46.63% |
| 2020 | CN¥11.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of Gan & Lee Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.42 Billion USD |
| MoneyControl | $6.42 Billion USD |
| MarketWatch | $6.42 Billion USD |
| marketcap.company | $6.42 Billion USD |
| Reuters | $6.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 inject… Read more